Form 4: Cardiff Oncology Director Rodney Markin Granted Stock Options
Insider Transaction Report
Cardiff Oncology, Inc. Director Rodney S. Markin was granted 40,565 stock options with an exercise price of $3.16, aligning his interests with shareholder value.
Summary
- Rodney S. Markin, a Director of Cardiff Oncology, Inc. (CRDF), acquired 40,565 stock options.
- The stock options have an exercise price of $3.16 per share.
- The transaction date for this grant was June 26, 2025.
- These options become exercisable on June 26, 2026, and are set to expire on June 26, 2035.
- Following this reported transaction, Mr. Markin beneficially owns a total of 222,865 derivative securities, specifically stock options.
Sentiment
Score: 7
Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with long-term shareholder value, though it's a routine compensation event rather than a significant operational or financial announcement.
Positives
- The grant of 40,565 stock options to Director Rodney S. Markin aligns his financial interests with the long-term performance and shareholder value of Cardiff Oncology, Inc.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing is a routine disclosure of an insider equity grant, which is a common component of executive and director compensation across various industries, designed to align management incentives with shareholder interests.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- The grant of stock options to Rodney S. Markin, a Director of Cardiff Oncology, Inc., constitutes a related party transaction, which is a common form of executive compensation.
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of the director's interests with the company's long-term performance and shareholder value.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 06/26/2025 | Date of stock option grant transaction. |
| 06/30/2025 | Signature date of the reporting person on the filing. |
| 06/26/2026 | Date the granted stock options become exercisable. |
| 06/26/2035 | Expiration date of the granted stock options. |
Recommendation
holdKeywords
Cardiff Oncology, CRDF, stock options, insider transaction, beneficial ownership, director, equity grant, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.